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1  | INTRODUCTION
The	XIV	Banff	Conference	for	Allograft	Pathology	was	held	March	27-	
31,	2017,	 in	Barcelona,	Spain,	 in	conjunction	with	 the	annual	meet-
ing	of	the	Catalan	Society	of	Transplantation.	A	total	of	479	delegates	
from	 23	 countries	 attended	 the	 conference,	 including	 pathologists,	
immunologists,	 physicians,	 surgeons,	 and	 immunogeneticists.	 The	
main	aim	of	the	2017	conference	was	to	revisit	the	current	diagnostic	
criteria	 for	 chronic	T	 cell–mediated	 rejection	 (TCMR),	 especially	 the	
significance	of	inflammation	in	areas	of	interstitial	fibrosis	and	tubu-
lar	 atrophy	 (i-	IFTA).	 In	 addition,	 discussion	 related	 to	 the	 relevance	
and	potential	integration	of	molecular	transplant	diagnostics	into	the	
Banff	 classification	was	 continued	 along	 the	 roadmap	 developed	 at	
the	2015	Banff	meeting.1	This	included	an	update	of	the	criteria	for	as-
sessing	molecular	features	related	to	antibody-	mediated	tissue	injury	
as	 a	 potential	 alternative/complement	 to	 donor-	specific	 antibodies	
(DSAs)	for	diagnosing	antibody-	mediated	rejection	 (ABMR).	 In	align-
ment	with	ongoing	efforts	of	the	American	Society	of	Transplantation	
(Transplant	 Therapeutics	 Consortium)	 and	 the	 American	 Society	 of	
Histocompatibility	and	Immunogenetics	(STAR	initiative	[Sensitization	
in	Transplantation:	Assessment	of	Risk]),	 the	Banff	2017	conference	
was	preceded	by	a	full-	day	premeeting	on	“New	Endpoints	for	Next-	
Generation	Clinical	Trials”	in	which	the	current	and	future	role	of	the	
Banff	classification	and	unmet	needs	for	the	field	with	regard	to	surro-
gate	endpoints	were	discussed.	In	addition,	the	meeting	included	as	a	
standing	item	an	update	session	on	the	ongoing	activities	of	the	Banff	
Working	Groups,	which	is	summarized	in	Table	1.
This	meeting	report	focuses	on	the	main	outcomes	from	the	Banff	
kidney	 sessions,	 and	 the	 resulting	changes	 to	 the	classification.	The	
main	conclusions	from	the	2017	Banff	liver,	heart,	lung,	pancreas,	and	
vascularized	composite	allograft	sessions	will	be	published	elsewhere.	
The	 next	 XV	 Banff	 meeting	will	 be	 held	 jointly	 with	 the	 American	
Society	of	Histocompatibility	and	Immunogenetics	 in	Pittsburgh,	PA,	
September	23-	27,	2019.
2  | DEFINING ENDPOINTS IN KIDNEY 
TRANSPLANTATION FOR NEXT- 
GENERATION CLINICAL TRIALS: 
PLACE OF THE BANFF SCHEME AND 
COMBINED ENDPOINTS
The	approval	of	novel	drugs	in	the	field	of	kidney	transplantation	has	
been	dampened	by	several	 factors.	One	of	 the	explanations	 for	 the	
failure	of	trials	testing	new	agents	has	been	the	success	of	the	“gold	
standard”	immunosuppression	demonstrated	in	the	Symphony	study	
and	on	the	other	hand,	the	relative	lack	of	success	of	new	agents.2	The	
US	Food	and	Drug	Administration	(FDA)/European	Medicines	Agency	
(EMA)-	approved	primary	endpoints,	such	as	1-	year	graft	and	patient	
survivals,	 are	 irrelevant	 today	 for	 superiority	 trials,	due	 to	excellent	
graft	and	patient	survival	in	the	overall	transplant	populations	(~95%)	
and	are	difficult	to	improve	further.	Designing	studies	with	5-	or	10-	
year	graft	and	patient	survival	as	primary	endpoints	are	unrealistic	in	
terms	 of	 costs,	 especially	 as	 transplantation	 is	 a	 small	 field/market	
The	kidney	sessions	of	the	2017	Banff	Conference	focused	on	2	areas:	clinical	implica-
tions	of	inflammation	in	areas	of	interstitial	fibrosis	and	tubular	atrophy	(i-	IFTA)	and	its	
relationship	to	T	cell–mediated	rejection	(TCMR),	and	the	continued	evolution	of	mo-
lecular	 diagnostics,	 particularly	 in	 the	 diagnosis	 of	 antibody-	mediated	 rejection	
(ABMR).	In	confirmation	of	previous	studies,	it	was	independently	demonstrated	by	2	
groups	that	i-	IFTA	is	associated	with	reduced	graft	survival.	Furthermore,	these	groups	
presented	that	i-	IFTA,	particularly	when	involving	>25%	of	sclerotic	cortex	in	associa-
tion	with	tubulitis,	is	often	a	sequela	of	acute	TCMR	in	association	with	underimmuno-
suppression.	 The	 classification	 was	 thus	 revised	 to	 include	 moderate	 i-	IFTA	 plus	
moderate	or	severe	tubulitis	as	diagnostic	of	chronic	active	TCMR.	Other	studies	dem-
onstrated	that	certain	molecular	classifiers	improve	diagnosis	of	ABMR	beyond	what	
is	possible	with	histology,	C4d,	and	detection	of	donor-	specific	antibodies	(DSAs)	and	
that	both	C4d	and	validated	molecular	assays	can	serve	as	potential	alternatives	and/
or	complements	to	DSAs	in	the	diagnosis	of	ABMR.	The	Banff	ABMR	criteria	are	thus	
updated	to	include	these	alternatives.	Finally,	the	present	report	paves	the	way	for	the	
Banff	scheme	to	be	part	of	an	integrative	approach	for	defining	surrogate	endpoints	in	
next-	generation	clinical	trials.
K E Y W O R D S
classification	systems:	Banff	classification,	kidney	transplantation/nephrology,	molecular	biology,	
pathology/histopathology,	rejection,	translational	research/science
*Correspondence
Mark	Haas	and	Alexandre	Loupy
Email:	mark.haas@cshs.org;	alexandreloupy@
gmail.com
     |  295HAAS et Al.
with	potentially	repositionable	drugs	known	already	for	their	adverse	
reaction	profiles.	Acute	rejection	is	also	recognized	as	a	primary	end-
point	 for	 clinical	 trials	 in	 transplantation	 by	 health	 authorities,	 but	
TCMR	and	ABMR	do	not	 have	 the	 same	 impact	 on	 graft	 outcome.	
Furthermore,	the	transplant	community	and	the	industry	aiming	to	in-
troduce	new	agents	are	addressing	these	issues	independently.
The	 Banff	 process	 has	 evolved	 from	 being	 a	 primarily	 pathology-	
driven	group	 to	a	more	comprehensive	and	multidisciplinary	approach	
that	includes	relevant	subject	matter	expertise	from	immunogeneticists,	
clinicians,	and	pathologists	with	the	goal	to	establish	and	refine	integrative	
diagnostic	standards	in	transplantation.	To	accelerate	the	development	of	
new	immunosuppressive	agents,	Banff	is	currently	working	closely	with	
regulatory	 agencies	 and	 international	 societies	 to	 define	 realistic	 and	
feasible	endpoints	and	approaches	 for	next-	generation	clinical	 trials.3,4 
Various	specialty	societies	and	consortia	have	identified	the	unmet	need	
for	the	validation	of	surrogate	endpoints	in	order	to	evaluate	responses	
to	therapy	and	predict	long-	term	kidney	allograft	outcomes.	During	the	
2017	Banff	 premeeting,	 those	 new	 challenges	were	 addressed	with	 a	
specific	focus	on	histologic,	immunologic,	and	molecular	endpoints.
2.1 | Histopathology as an endpoint
Rejection	 episodes	 confirmed	 by	 histology	 are	 recognized	 as	 the	
cornerstone	 of	 diagnosis	 and	 prognosis	 in	 kidney	 and	 transplanta-
tion	pathology.	However,	the	current	FDA/EMA-	approved	surrogate	
histologic	 endpoint,	 biopsy-	confirmed	 acute	 rejection	 (BCAR),	 is	 no	
longer	 reflecting	 current	 diagnostics	 in	 renal	 transplantation,	where	
the	impact	of	acute	TCMR	on	outcome	has	declined.	As	an	example,	
in	the	BENEFIT	Study,	BCAR	was	used	as	primary	endpoint	for	non-
inferiority,	 and	 there	was	more	BCAR	 (TCMR)	 in	 the	 arm	 receiving	
belatacept	(vs	cyclosporine),	but	this	did	not	lead	to	a	higher	rate	of	
graft	loss	in	the	long	term	as	shown	by	the	BENEFIT-	EXT	study.5,6	To	
regain	usefulness	as	primary	endpoints	for	trials	in	kidney	transplanta-
tion,	histologic	markers	need	to	follow	a	validation	process	as	outlined	
during	the	Banff	meeting	(Table	2A).
2.2 | Intragraft gene expression as an endpoint
In	Table	2B,	we	listed	our	recommendations	on	best	practices	for	mo-
lecular	endpoints	in	clinical	trials.	Potential	diagnostic	and	prognostic	
molecular	endpoints	and	biomarkers	are	listed	in	Tables	3	and	4.
2.3 | Anti- HLA DSAs as an endpoint
To	be	a	potential	surrogate	endpoint,	anti-	HLA	DSAs	have	not	only	to	
be	considered	within	the	context	of	their	potential	 limitations	(titra-
tion	rather	than	mean	fluorescence	intensity	to	reveal	oversaturation)	
but	also	by	integrating	their	properties	(eg,	complement	activating	ca-
pacity,	IgG	subclasses,	cytotoxic	effect).	However,	current	shortcom-
ings	of	DSA	testing	(variability	in	test	methods,	diagnostic	threshold	
definitions,	clinical	significance	standards)	are	known	to	limit	its	utility	
as	a	sole	endpoint.	Ongoing	efforts	of	the	STAR	initiative	are	aiming	
to	address	these.
2.4 | Potential of innovative combined endpoints
The	participants	in	the	2017	Banff	premeeting	support	a	path	toward	
integrated	diagnostic	 and	prognostication	 systems	by	 exploring	op-
portunities	 provided	 by	 advanced	 data	 and	 applied	 statistics	 from	
the	 field	of	machine	 learning.7	To	 this	end,	 the	Banff	group	 formed	
a	new	working	group	on	surrogate	endpoints	aimed	at	fostering	col-
laboration	with	other	professional	 societies	and	regulatory	agencies	
on	 the	common	goal	 to	develop	a	path	 forward	 to	successful	next-	
generation	 multicenter	 trials	 and	 approval	 of	 novel	 drugs	 in	 solid	
organ	transplantation.
3  | 2017 REVISIONS TO THE BANFF 
CLASSIFICATION
3.1 | T cell–mediated rejection
The	Banff	2015	meeting	report	noted	for	the	first	time	that	chronic	
active	TCMR	may	be	manifest	 in	 the	 tubulointerstitial	 as	well	 as	 in	
the	 vascular	 compartment.1	 However,	 the	 current	 Banff	 classifica-
tion	does	not	provide	specific	criteria	regarding	how	tubulointerstitial	
changes	 should	be	 considered	 for	diagnosing	 chronic	 active	TCMR,	
although	Banff	 consensus	 criteria	 for	 semiquantitatively	 scoring	 in-
flammation	in	areas	of	IFTA	(i-	IFTA)	as	a	histologic	lesion	have	been	
established.	Although	potential	problems	 in	scoring	 i-	IFTA	might	be	
anticipated	 as	 scattered	 inflammatory	 cells	 are	 often	 seen	 in	 what	
might	be	 considered	by	many	pathologists	 to	be	bland	 fibrosis,	 the	
Paris	group8	reported	good	agreement	among	3	pathologists	in	grad-
ing	i-	IFTA	according	to	the	Banff	2015	criteria,	with	complete	agree-
ment	between	all	3	pathologists	 in	101	(67%)	of	150	cases,	and	a	κ 
value	of	.62.
The	 impact	 of	 i-	IFTA	 on	 graft	 outcomes	was	 first	 suggested	 by	
the	finding	of	Mengel	et	al9	that	total	cortical	 inflammation	(Banff	ti	
score)	was	more	predictive	of	 graft	 loss	 than	 inflammation	 in	nons-
clerotic	 areas	 of	 cortex	 (Banff	 i	 score).	 Independently,	 the	 DeKAF	
study10	 showed	a	strong	association	between	the	severity	of	 i-	IFTA	
and	graft	loss,	far	stronger	than	that	of	IFTA	alone.	Degrees	of	inflam-
mation	involving	>25%	of	areas	of	cortex	with	IFTA	(corresponding	to	
Banff	2015	i-	IFTA	scores	2	and	3)	were	significantly	associated	with	
an	increased	risk	of	graft	loss	in	multivariate	models.10	These	findings	
were	independently	validated	by	recent	studies	of	Lefaucheur,	Loupy,	
and	coworkers8	and	Nankivell	et	al11	The	amenability	of	i-	IFTA	to	im-
munosuppressive	 therapy	 remains	 an	 important	 question,	 and	 find-
ings	 of	 the	DeKAF	 study	 showed	 that	 the	 effect	 of	 i-	IFTA	on	 graft	
survival	was	not	significantly	affected	by	 treatment	 for	concomitant	
acute	TCMR.10	Still,	data	presented	by	the	Paris	group8	showed	that	
i-	IFTA	 is	 related	 to	 underimmunosuppression,	 and	 both	 this	 group	
and	Nankivell	et	al11	found	that	i-	IFTA	is	typically	preceded	by	TCMR.	
Furthermore,	 the	 frequency	 of	 i-	IFTA	 in	 protocol	 biopsy	 specimens	
has	declined	in	the	era	of	tacrolimus-	based	immunosuppression	com-
pared	with	 that	 of	 cyclosporine-	based	 immunosuppression.11	 Taken	
together,	these	findings	suggest	that	i-	IFTA,	at	least	in	many	instances,	
is	related	to	chronic	underimmunosuppression	and	thus	can	represent	
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TABLE  1 Update	on	active	Banff	working	groups
Leaders Issues to address Group progress/future plans
TCMR V.	Nickeleit,	 
P.	Randhawa
Possible	incorporation	of	i-	IFTA	into	
classification;	possible	elimination	of	
borderline	category;	reevaluate	
thresholds	for	i	and	t	and	possible	
addition	of	other	findings	(eg,	edema)	
to	TCMR	diagnostic	criteria.
To	this	point	compiled	81	cases	of	“pure”	TCMR	with	complete	clinical/
pathologic	data	sets,	and	an	additional	140	cases	with	incomplete	data.	
More	cases	of	“pure”	TCMR	with	complete	pathologic	and	clinical	data	
for	evidence-	based	analysis	of	TCMR/borderline	thresholds	are	
required;	these	cases	need	to	have	documented	absence	of	DSA	and	
sufficient	follow-	up.
Survey	among	renal	pathologists	(including	very	experienced)	revealed	
nonuniform	application	of	current	Banff	TCMR	cutoffs,	consideration	
of	non-	Banff	lesions	in	TCMR	diagnosis,	grading	or	nongrading	of	
i-	IFTA.
See	also	discussion	of	i-	IFTA	scoring	and	clinical	relevance	for	diagnosis	
of	chronic	active	TCMR.
Sensitized L.	Cornell,	 
E.	Kraus,	 
S.	Bagnasco,	
C.	Schinstock,	
D.	Dadhania
Define	criteria	for	highly	sensitized	
patients	(HS),	determine	consensus	
for	what	personnel	and	facilities	are	
needed	for	centers	to	perform	
transplantation	in	HS	recipients,	
standardize	the	definitions	related	to	
management	of	sensitized	transplant	
recipients.
Evaluate	current	practices	of	centers	
performing	renal	transplants	in	
sensitized	recipients.
Evaluate	how	clinicians	interpret	and	
apply	Banff	nomenclature,	and	
recommend	changes	to	wording	of	
classification	to	optimize	the	use	of	
Banff	data	in	patient	care.
Survey	regarding	clinical	practice	related	to	highly	sensitized	patients	
indicates	that:
•	 Clinicians	often	fail	to	recognize	chronic	elements	of	ABMR	(eg,	cg	
>0)
•	 Clinicians	more	likely	to	consider	a	diagnosis	of	chronic,	active	ABMR	
if	C4d	is	negative,	even	if	there	is	no	TG,	PTCBML,	or	IFTA
•	 The	term	“acute”	(in	acute/active	ABMR)	is	confusing	to	clinicians,	
and	consequently	it	has	been	removed	from	the	Banff	classification—
see	Table	5
•	 Further	improve	communication	between	pathologists	and	clinicians	
regarding	reporting	of	biopsy	findings	in	HS,	including	the	presence	
of	C4d-negative	early	ABMR
Molecular M.	Mengel,	 
B.	Sis
Develop	consensus	guidelines	for:
Circumstances	under	which	it	is	
advisable	to	apply	molecular	analysis	
to	renal	biopsy	tissue	and/or	serum/
urine	collected	at	the	time	of	
biopsy—also	see	Tables	4	and	6
Standardize	diagnostic	criteria	and	
procedures	for	a	gene	expression	
analysis	approaches	in	renal	
transplantation.
Further	data	from	experiences	with	gene	expression	analysis	applied	to	
FFPE	tissue	was	presented:
•	 the	method	can	reproducibly	be	applied	to	almost	any	FFPE	sample	in	
different	species
•	 multicenter	studies	are	under	way	or	planned	for	applications	in	
kidney,	heart,	pancreas,	and	lung	transplantations
Electron	
micros-
copy
C.	Roufosse,	
H.K.	Singh
Interobserver	variability	and	clinical	
correlations	in	cg1a	lesions	and	
PTCBML	scoring.	Potential	
refinement	of	PTCBML	scoring	
criteria.
Criteria	for	amount	of	GBM	duplica-
tion	and	immune	complex-	type	
deposits	allowable	in	cg1a.
Multicenter	study	of	the	natural	
history,	associations	and	predictive	
value	of	cg1a	and	PTCBML	using	
consensus	criteria.	Define	possible	
lower	levels	of	PTCBML	and	
endothelial	cell	changes	that	
represent	earlier	and	possibly	
reversible	levels	of	injury	(compared	
wih	level	of	PTCBML	required	to	
diagnose	chronic	active	ABMR	in	
Banff	2013).
A	survey	showed	that	current	Banff	guidelines	do	not	provide	enough	
detail	regarding	when	to	do	EM,	and	that	current	guidelines	are	often	
not	followed	due	to	cost	restrictions	or	limited	access	to	EM 
Future	studies	will	focus	on:
•	 How	reversible	is	cg1a?
•	 What	is	the	prognostic	significance	of	cg1a	compared	with	that	of	
overt	TG?
•	 Is	there	a	level	of	PTCBML,	lower	than	that	required	to	diagnose	
chronic	active	ABMR	in	Banff	2013,	that	is	useful	in	the	diagnosis	of	
early	chronic	ABMR,	and,	if	so,	is	this	potentially	reversible	with	
treatment	for	ABMR?
Goals:
•	 To	create	a	comprehensive	teaching	module	for	TG	and	PTCBML	
evaluation	and	guidelines	for	diagnosis	of	ultrastructural	changes	with	
a	follow-up	test	using	digital	images
•	 Multicenter	validation	of	diagnostic	criteria	and	final	
recommendations
(Continues)
     |  297HAAS et Al.
Leaders Issues to address Group progress/future plans
Thrombotic	
microangi-
opathy	
(TMA)
M.	Afrouzian,	
J.	U.	Becker,	
H.	Liapis,	 
S.	Seshan
Establish	uniform	diagnostic	criteria	
for	TMA.
Determine	the	frequency	with	which	
TMA	occurs	in	renal	allograft	biopsy	
specimens.
Determine	if	there	are	specific	
features	of	TMA	in	renal	allografts	
that	help	resolve	the	differential	
diagnosis	of	the	TMA	when	the	
cause	is	not	readily	apparent	from	
clinical	history,	DSA/C4d,	etc.
Survey	of	26	centers	showed	TMA	diagnosed	in	5%-	10%	of	biopsy	
specimens	in	42%	of	centers,	<5%	in	35%,	10%-	20%	in	23%	of	centers.
Focus	future	efforts	on	working	with	other	groups	(eg,	KDIGO,	ERKnet)	
in	defining	TMA	uniformly	in	native	and	transplanted	kidneys.
Compare	and	contrast	features	of	TMA	in	known	cases	of	CNI-	related	
TMA	(from	native	kidneys	of	recipients	of	other	solid	organs),	TMA	in	
the	setting	of	well-	documented	ABMR	(DSA+,	C4d+),	and	recurrent	
aHUS	to	assess	differences	in	morphologic	and	other	(eg,	laboratory,	
molecular)	features	between	these	that	will	be	potentially	useful	in	
determining	the	most	likely	etiology	in	TMA	cases	where	the	latter	is	
not clear.
Recurrent	
glomerular	
disease
N.	Alachkar,	S.	
Bagnasco
Establish	pathologic	guidelines	for	
early	recurrence	of	glomerular	
diseases,	including	FSGS,	IgA	
nephropathy,	and	MPGN/C3GN.
What	are	frequencies,	clinical	
manifestations,	and	pathologic	
characteristics	of	recurrent/de	novo	
glomerular	disease?	Can	any	of	these	
predict	recurrence	and/or	graft	
outcomes?
Understand	the	pathologic	changes	of	
recurrent	glomerular	diseases	
occurring	concurrently	with	rejection	
and	other	transplant-	associated	
lesions.
Biopsy	specimens	are	now	collected	from	5	centers	and	preliminary	
studies	confirm	IgA	nephropathy	and	FSGS	as	the	most	prevalent	
recurring	diseases. 
Future	directions: 
Are	there	clinical	and/or	pathologic	features	of	the	native	disease	that	 
	predict	likelihood	of	recurrence? 
Are	there	clinical	and/or	pathologic	features	of	the	recurrent disease in  
	the	allograft	that	predict	graft	loss? 
Which	pathologic	analyses	(IF,	EM,	others)	are	needed	for	optimal	and	 
	early	diagnosis	of	recurrent	disease? 
Is	the	apparent	association	of	recurrent	glomerular	disease	with	acute	 
		rejection	related	to	biopsy	bias	(ie	incidental	discovery	of	recurrent	 
		disease	in	biopsies	done	to	r/o	rejection),	under-	immunosuppression,	 
		or	both?
Surrogate	
endpoints 
(new	
working	
group)
A.	Loupy,	 
B.	Orandi
Respond	to	the	unmet	need	raised	by	
the	FDA	meeting	held	in	Arlington	in	
2015:	build	a	validated	multicenter	
composite	scoring	system	integrating	
histopathology	with	other	relevant	
allograft	biomarkers	to	predict	
long-	term	allograft	outcome.
See summary of Banff pre-meeting “New Endpoints for Next Generation 
Clinical Trials”
HIV+/HIV+ 
renal 
trans-
plants 
(new	
working	
group)
S.	Bagnasco Are	there	specific	issues/difficulties	in	
diagnosing	transplant-	associated	
pathologic	lesions	(TCMR,	ABMR,	
others	and	components	of	these)	in	
the	setting	of	concurrent	HIV-	
associated	pathology	(related	to	the	
virus	itself	and	to	anti-	retroviral	
therapy).
Do	the	incidence,	pathology,	and	
therapeutic	response	of	rejection	in	
cases	of	HIV+/HIV+	renal	transplan-
tion	differ	from	those	with	HIV-	
donor	kidneys	transplanted	into	
HIV-	recipients	and	into	HIV+	
recipients.	If	so,	how	are	these	
differences	manifest?
Overall,	develop	a	set	of	evidence-	
based	guidelines	for	HIV+/HIV+	
renal transplants.
Efforts	are	underway	to	standardize	the	histological	assessment	of	
HIV-	associated	nephropathies	in	native	kidneys	(eg,	KDIGO).	Any	
scoring	of	such	lesions	in	transplants	should	follow	the	native	kidney	
criteria.	Subsequently	transplant	specific	pathologies	can	be	defined.	
Further	efforts	of	this	BWG	will	focus	on	working	with	the	native	
kidney	groups	on	standardizing	the	HIV-	related	pathology	scoring.
Banff	rules	
and 
dissimi-
 nation 
(new	
working	
group)
J.	U.	Becker,	 
C.	Roufosse
Collation	of	contents	of	previous	
Banff	reports	in	a	central	web-	based,	
updatable	repository	including	
diagnostic	parameters,	definitions	
and	rules.
Elaboration	of	a	minimum	dataset	and	
algorithms	for	application	of	Banff	
classification.
Finalisation	of	the	collation	of	current	content	during	a	meeting	in	
London,	UK	in	September	2017.
Preparation	of	a	review	manuscript	with	contents	of	previous	Banff	
reports	up	to	2015.
Incorporation	of	possible	changes	in	Banff	2017	report	to	content	for	
the	web-	based	repository	in	2018.
TABLE  1  (Continued)
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chronic	 active	TCMR.	 Inflammation	 in	non-	IFTA	and	 IFTA	areas	 can	
coexist	 in	the	same	biopsy	specimen.	Such	biopsy	specimens	should	
still	be	diagnosed	as	chronic	active	TCMR	and	not	labeled	acute	plus	
chronic	active	TCMR,	because	the	latter	already	addresses	the	acute/
active	component	 in	 the	 rejection	process.	 In	other	words,	a	biopsy	
fulfilling	 the	 diagnostic	 criteria	 for	 chronic	 active	TCMR	 should	 not	
be	given	a	second	diagnosis	of	Borderline	or	acute	TCMR.	However,	
biopsies	with	chronic	active	TCMR	can	have	an	additional	diagnosis	
of	ABMR.	 In	 general,	 i-	IFTA	 likely	 reflects	 a	 response	 to	wounding	
of	 injured	nephrons	and	renal	tissue,	as	shown	by	molecular	studies	
showing	that	any	progressing	chronic	kidney	diseases	are	associated	
with	 increased	expression	of	acute	kidney	 injury	transcripts.	Thus,	 i-	
IFTA	is	the	morphologic	correlate	of	active	injury,	compared	with	IFTA	
with	no	inflammation,	and	predicts	disease	progression	as	part	of	an	
active	injury	process	damaging	the	nephron	and	potentially	warranting	
treatment.12,13
Clearly,	 i-	IFTA	 is	 not	 a	 specific	 lesion,	 and	 adding	 i-	IFTA	 by	 it-
self,	even	if	moderate	to	severe,	to	the	classification	as	diagnostic	of	
chronic	 active	TCMR	 does	 not	 appear	warranted	 based	 on	 present	
data.	 It	 is	well	 known	 that	many	 other	 disease	 processes,	 including	
BK	 virus	 infection,	 pyelonephritis,	 ABMR,	 recurrent	 glomerulone-
phritis,	and	obstruction,	may	at	some	point	present	with	 i-	IFTA.	The	
nonspecificity	 of	 i-	IFTA	 for	 rejection,	 proved	 by	 the	 fact	 that	 it	 oc-
curs	in	native	kidneys,	was	the	main	reason	why	i-	IFTA	and	tubulitis	
in	atrophic	tubules	was	specifically	excluded	from	the	classification	at	
the	first	Banff	meeting.	However,	since	1991,	immunosuppression	has	
changed	 and	 graft	 survival	 improved	with	more	 patients	 presenting	
late	 posttransplantation	with	 i-	IFTA	 requiring	 differential	 diagnostic	
resolution	to	guide	treatment.	Based	on	the	most	recent	data	taking	
this	 evolution	 into	 account,	 i-	IFTA	 is	 likely	 to	 be	 a	manifestation	of	
TCMR	when	associated	with	other	 features	of	ongoing	T	cell–medi-
ated	alloimmunity,	such	as	tubulitis	or	a	history	of	TCMR	episodes	in	a	
patient,	especially	after	excluding	other	diseases	known	to	be	associ-
ated	with	i-	IFTA	(eg,	BK,	ABMR,	GN,	obstruction).	The	study	from	the	
Paris	group	did	show	that	i-	IFTA	was	significantly	correlated	with	the	
presence	of	tubulitis,	in	both	scarred	and	nonscarred	areas	of	the	cor-
tex.8	Thus,	at	present	and	to	minimize	overdiagnosis,	tubulointerstitial	
lesions	of	chronic	active	TCMR	have	been	added	to	the	working	clas-
sification	 (Table	5)	as	a	combination	of	 i-	IFTA	and	tubulitis	 involving	
all	but	severely	atrophic	tubules,	with	moderately	high	thresholds	for	
both	(i-	IFTA2-	3;	t2-	3),	a	requirement	for	inflammation	involving	>25%	
of	the	total	cortex	present,	and	other	differential	diagnoses	known	to	
be	associated	with	i-	IFTA	(eg,	chronic	pyelonephritis,	BK	nephropathy)	
being	ruled	out.	Notably,	Lefaucheur	et	al8	found	that	i-	IFTA	scores	of	
2	and	3,	but	not	1,	as	well	as	t2	and	t3	tubulitis	(but	not	t1)	within	areas	
of	IFTA,	excluding	severely	atrophic	tubules,	were	associated	with	an	
increased	rate	of	graft	loss.	This	conservative	approach	has	served	the	
Banff	 group	well	 in	 the	past,	with	 the	 introduction	of	C4d-	negative	
ABMR.14	As	with	the	latter	(see	later),	future	modifications	will	be	con-
sidered	as	new	data	emerge	from	the	Banff	TCMR	working	group1 as 
well	as	from	other,	independent	investigators.	Key	issues	here	concern	
the	 threshold	values	of	 individual	histologic	 lesions	needed	 to	diag-
nose	chronic	active	TCMR,	whether	the	Banff	i-	IFTA	score	or	ti	score	
is	more	predictive	of	graft	outcomes,	association	with	nonadherence	
and	 underimmunosuppression,	 and	 possibly	 response	 to	 newer	 im-
munosuppressive	therapy.	Response	to	 increase	 immunosuppressive	
therapies	should	be	studied,	as	well	as	whether	molecular	parameters	
associated	with	TCMR15,16	may	be	useful	in	diagnosis.
At	 this	point,	 there	 is	no	borderline	or	 suspicious	category	 for	
chronic	 active	 TCMR,	 particularly	 as	 this	 category	 within	 acute	
TCMR	has	proved	to	be	troublesome	for	treating	clinicians	and	even	
for	pathologists	to	define	(see	Tables	3	and	4	of	ref.	1).	Furthermore,	
low	levels	of	i-	IFTA	(i-	IFTA	1)	and	mild	tubulitis	within	foci	of	IFTA	
were	not	correlated	with	graft	 survival	 in	 the	study	of	Lefaucheur	
et al.8
Figure	1	depicts	 lesions	of	chronic	active	TCMR	grades	IA	(panels	
A	and	B)	and	IB	(panels	C	and	D).	Both	show	extensive	i-	IFTA,	with	the	
main	 difference	 being	 the	 extent	 of	 tubulitis,	 being	moderate	 (t2)	 in	
grade	IA	and	severe	(t3)	in	grade	IB.	Interstitial	edema	is	present	as	well,	
although	the	latter	is	not	a	requirement	for	i-	IFTA	and	the	inflammation	
may	be	present	 in	areas	of	denser,	more-	evolved	fibrosis	as	 is	shown	
in	 Figure	2,	which	 depicts	 3	 other	 biopsy	 specimens	 showing	 i-	IFTA	
with	varying	densities	of	 interstitial	 fibrosis	and	degrees	of	 interstitial	
TABLE  2 Banff	recommendations	on	best	practice	for	pathology	
and	molecular	endpoints	in	clinical	trials
A.	Banff	recommendations	on	best	practices	for	pathology	endpoints	
in clinical trials
Pathologists	to	participate	in	the	design	and	choice	of	endpoints
Panel	of	pathologists	(3	optimal	to	avoid	a	tie)
Adjudication	mechanism	(how	discordance	between	pathologists	is	
addressed)
Whole	slide	digital	images	for	centralized	slide	review
Auditable	assessments	(scoring	that	can	be	reviewed	and	audited	
externally)
Granular	scoring	(detailed	phenotyping	and	lesions	scoring	
considered	for	end-	points)
Quantitate	changes	(use	of	continuous	scores	and	percentages	
rather	than	semi-	quantitative	scoring)
Centralized	processing	of	ancillary	testing,	eg	IHC	stains
B.	Banff	recommendations	on	best	practices	for	molecular	endpoints	
in clinical trials
The	primary	effort	should	be	on	applying	molecular	studies	to	
biopsies
Large	Reference	data	sets	should	be	well	annotated
High	reproducibility/replication	of	assays
Pathogenesis	based	transcript	strategy	appears	useful	and	can	be	
completed	by	classifier	approaches	(no	single	gene	test	is	specific)
Centralized	testing	advantageous	for	multi-	center	trials	molecular	
analysis
Proper	methodological	approaches	are	needed	(for	both	assay	
performance	and	data	analysis,	...)	Adds	statistical	power,	
potentially	reducing	sample	size	and	costs
Quality	Assurance	is	mandatory	(inter-	laboratory,	inter-	platform	
and	inter-	assay	reproducibility;	development	of	standardized	
positive	and	negative	controls	and	quantitative	diagnostic	
reference	standard)
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inflammation,	 edema,	 and	 tubulitis	 using	 3	 different	 histologic	 stains	
(hematoxylin	 and	 eosin,	 periodic	 acid–Schiff,	 and	Masson	 trichrome).	
The	silver-	stained	sections	in	Figure	1	show	tubulitis	in	mildly	to	mod-
erately	atrophic	tubules	(best	evident	in	panels	B	and	D),	and	both	of	
these	 biopsy	 specimens	 also	 show	 some	 severely	 atrophic	 tubules.	
The	 latter	 tubules	are	defined	by	having	a	diameter	<25%	of	 that	of	
unaffected	or	minimally	affected	tubules	on	the	biopsy,	often	with	an	
undifferentiated-	appearing,	 cuboidal,	 or	 flattened	 epithelium	 (or,	 in	
some	 cases,	 even	 loss	 of	 epithelium	with	 denudation	 of	 the	 tubular	
basement	membrane)	and	pronounced	wrinkling	and/or	thickening	of	
the	tubular	basement	membrane.	This	definition	of	severely	atrophic	tu-
bules	also	includes	very	small,	endocrine-	like	tubules	with	very	narrow	
lumens,	 although	 the	basement	membranes	of	 the	 latter	may	not	be	
thickened.	Frequently,	severely	atrophic	tubules	will	show	tubulitis	even	
if	 there	 is	minimal	accompanying	 interstitial	 inflammation;	 this	 is	 true	
even	in	native	kidney	biopsy	specimens.	Therefore,	tubulitis	in	these	tu-
bules	is	presently	not	considered	toward	the	diagnosis	of	chronic	active	
TCMR	(Table	5),	although	this	point	requires	further	study,	which	will	be	
done	by	the	TCMR	working	group.	The	interobserver	reproducibility	of	
pathologists	to	distinguish	severely	atrophic	tubules	from	less	atrophic	
ones	will	also	need	further	testing,	although	encouraging	results	were	
reported	by	the	Paris	group.8	They	reported	a	complete	agreement	rate	
between	3	pathologists	of	72%	and	a	κ	value	of	.58	in	grading	tubulitis	
in	areas	of	IFTA	excluding	severely	atrophic	tubules,	although	the	latter	
were	not	defined	by	a	specific	reduction	in	size.
3.2 | Antibody- mediated rejection
Several	potential	updates	to	the	Banff	2015	criteria	for	ABMR	were	
considered.	The	most	 important	of	 these	concerned	potential	alter-
natives	 to	 the	DSA	criterion	 in	 the	diagnosis	of	ABMR.	Evidence	 in	
support	of	 incorporation	 into	the	classification	of	2	such	alternative	
markers,	C4d	and	molecular	ABMR	assessment17-20	consisting	of	ei-
ther	a	set	of	antibody-	mediated	tissue	injury–associated	genes,	or	a	
respective	molecular	classifier,	was	reviewed	at	the	2017	Banff	con-
ference	and	is	summarized	in	the	following	section.	In	a	postmeeting	
poll	answered	by	63	experts,	incorporation	of	these	markers	into	the	
Banff	classification	for	ABMR	was	favored	by	a	majority,	and	this	 is	
reflected	in	the	revised	criteria	for	the	diagnosis	of	ABMR	described	in	
this	2017	revision	(Table	5).	As	C4d	positivity	is	now	considered	an	al-
ternative	for	DSA	criterion	in	cases	where	DSA	testing	is	not	available	
or	potentially	false	negative,	all	biopsy	specimens	showing	at	least	fo-
cally	positive	C4d	staining	now	fall	into	1	of	3	diagnostic	categories:	
active	ABMR,	chronic	active	ABMR,	and	C4d	staining	without	histo-
logic	evidence	of	rejection	(Table	5).	The	potentially	confusing	catego-
ries	of	“suspicious	for	active	ABMR”	and	“suspicious	for	chronic	active	
ABMR”	are	now	eliminated.	It	should	be	stressed	here	that	these	new	
criteria	allowing	for	the	diagnosis	of	ABMR	in	the	absence	of	detect-
able	DSAs	do	not	constitute	recognition	of	“antibody-	negative	ABMR”	
in	the	sense	that	Banff	2013	first	recognized	C4d-	negative	ABMR.	It	is	
rather	an	acceptance	of	the	fact	that	current	DSA	testing	methods	do	
not	detect	all	antibodies	that	are	potentially	injurious	to	the	allograft,	
including	 some	 non-	HLA	 antibodies,	 and	 that	 using	 the	 alternative	
markers	discussed	next	will	allow	us	to	diagnose	and	treat	a	small	but	
significant	subset	of	cases	of	ABMR	where	current	DSA	testing	meth-
ods	fall	short	or	are	not	available.	Finally,	DSA	testing	remains	strongly	
recommended	 in	all	 cases	with	biopsy	 specimens	meeting	 the	mor-
phologic	criteria	(criteria	1	and	2)	for	active	or	chronic	active	ABMR	
(Table	5),	not	only	for	ABMR	diagnosis	but	also	for	risk	stratification,	
evaluating	the	response	to	treatment	and	further	patient	monitoring.	
A	minor	consideration	in	the	revised	classification,	discussed	later,	in-
volves	the	removal	of	the	word	“acute”	from	“acute/active	ABMR.”
TABLE  3 Prime	gene	list	of	published	studies	in	kidney	transplantation	and	related	diagnoses.	Courtesy	by	Dr.	Robert	Colvin	(Massachusetts	
General	Hospital)	and	Dr.	Alexandre	Loupy	(Paris	Translational	Research	Center	for	Organ	Transplantation	INSERM	U970)
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on Tolerance (Blood) GoCAR Glomerulus TCMR Constant rej IFI27 ABMR DSAT TCMR MYB ENG RHOJ
Adam Vitalone Wherry Rebolo-Mesa O'Connell APOL1 Halloran NIH IGF Halloran Halloran Venner PHEX ERG ROBO4
CAV1 ADAMDEC1 IFNG BCL2 CITED4 CD244/2B4 ATXN3 ASB15 COL4A3 ADAMDEC1 ADAM8 IL-10 APOBEC3A CDH13 ADAMDEC1 PSME2 EVA1C S1PR1
CD34 AIM2 IL12RB1 CD4 EDA BCL6 BCL2A1 CHCHD10 COL4A4 ANKRD22 ANP IL-1R C21orf63 CDH5 AIM2 PSTPIP1 FCGR3A S1PR5
CD74 ANKRD22 IL18BP CXCL10 SLC19A3 BTLA EEF1A1 FJX1 COL4A5 BTLA BASP1 IL-2RA CAV1 COL13A1 ANKRD22 PTPN7 FGFBP2 SDR16C5
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CDH5 APOL2 LAG3 GZMB SLC25A15 CTLA4 IGLC1 KLH13 NPHS1 CD72 CASP1 IL10RA CDH13 DARC APOL2 SH2D1A GNLY SH2D1B
CX3CR1 BTLA LAIR1 IL1RL1 SLC4A1 EOMES MS4A4A MET NPHS2 CD8A CASP3 IL8 CDH5 FGFBP2 BTLA SIRPG HEG1 SOX7
CXCL11 CD274 LAP3 IL4 TMEM178 GATA3 NFKBIA RNF149 CD96 CASP4 INDO CETP GNG11 CD274 SLA HSPA12B TEK
DARC CD28 LCP2 WARS TRAF4 IKZF2 RAB40C RXRA Misc CXCL13 Cathepsin-S INFG CRHBP GNLY CD28 SLAMF8 HYAL2 TFF3
LCCGNFIADCIA5CNIRES3PIAFNT01LIBYMD3DC2PBFGF -2 IP-30 CX3CR1 HLA-DRB3 CD3D SP140 ICAM2 THBD
GATA3 CD72 PHEX Macrophages AKI 1FS4MT5REI4AIS8TS27DC2MACI01LCXC02GSI81LCC3FZKIERIA4YRPS12LI
GNLY CD84 PSME2 ARG1 Einecke LAG3 TOLS ST5 CCL5 IL12RB1 CCL19 JAK1 CXCL11 KLRF1 CD84 TAP1 IFI27 TM4SF18
IFNG CD86 PSTPIP1 CD163 CPA3 NFAT Colvin TGIF1 CCR4 IL21R CCL5 JAK2 DARC MALL CD86 TIGIT IL18RAP TRDV3
KLF4 CD8A PTPN7 CD206 CTSS PD1 BDCA2 WNT9A CCR5 LAG3 CCR5 L-selecn ECSCR MYBL1 CD8A TNFSF8 KLF2 VEGFC
B8DC5MGP2PBFGFIDGyL41DCGH551RIMC4CELC12LCC472DC/1LDPA3RGCF86DC3SERRARB8DC1FRLK ABMR KLRF1 VWF
MALL CD96 SH2D1A LGALS3 HAVCR1 PDL2 CD197/CCR7 CADI Progression IL17 OR2I1P CD2 MMP-9 GNG11 PLA1A CD96 Venner LAYN
MYBL1 CTLA4 SIRPG VEGFA ITGB6 PRDM1 EPO Menon JCI IL2 PDCD1LG1 CRACC Perforin GNG11 PLAT CTLA4 ACVRL1 LDLR
PALMD CXCR6 SLA LCN2 TBX21 FOXP3 SHROOM3 MIF PLA2G2D CTLA-4 Plscramblase GNLY ROBO4 CXCR6 AGR2 LHX6
PECAM1 DUSP2 SLAMF8 Plasma cells LTF TGFB1 IDO COL1A1 MS4A1 PTPN7 CXCL10 PSMB10 KLF4 SH2D1B DUSP2 AGR3 LST1
LLAM1AXNA2HZE7XOS1XOEM8BMSP11LCXC4LMCSRTIG/81FSRFNT1ANFITIGIT11FGEM1MDRP041PS2HZEA1ALP
PLAT FAM26F ST8SIA4 IGHG1 NFKBIZ TIM3 ITGAX/CD11C Matrix SH2D1A CXCL9 PSMB9 PALMD TEK FAM26F APOBEC3A MCAM
1A1LOCATLTMNN2GHGI1PATB1RGCF01BMSP Virus SIRPB2 CXCR3 PSME1 PGM5 TM4SF18 FCGR1B CAV1 MEOX1
RHOJ FGD2 TIGIT IGHG3 OSMR AMR NOS2 COL3A1 BK large T Ag SLA CXCR4 STAT1 PLA1A FGD2 CCL3 MMRN2
ROBO4 GBP5 TNFSF8 IGHG4 RARRES1 Roufosse PDPN COL4A1 BK VP1 SLAMF8 FcGRI TANK RAMP3 GBP5 CD160 MYBL1
RPS6 GIMAP5 IGHM SOD2 VWF TNFRSF3 COL5A1 CMV UL83 SP140 FNGR1 TAP1 RAPGEF5 GIMAP5 CD55 NOS3
RPS6KB1 ICOS CRM IGHA1 SPLI CDH5 TNFSF3 FN1 EBV LMP2 THEMIS GBP1 Tapasin ROBO4 ICOS CD59 NPDC1
SELE IFI30 Sarwal IGKC VCAN SOX7 Housekeeping TIGIT GBP2 TGF-B1 SOST IFI30 CDH13 PALMD
SH2D1B BASP1 IGLC1 VMP1 PECAM1 Mast cells Nanostring TNFSF8 GBP4 TIMP1 SOX7 IFNG CDH5 PECAM1
SOX7 Eculiz Resp CRAD6DC Mengel DDX50 TOX2 GZMA TLR8 TM4SF18 IL12RB1 CFLAR PGM5
TBX21 Lefaucheur ALHMIRTBSUG3APCB1D2HS3XNUR7DC - A1ALP1A31LOCPB81LIDRTFNTA
ALH3CADH1BASPT1RC3XC1PAT01LCXC4LCCKET - 2KLP2PIRCR12LIFWV01FSFNTE
ALH1ZAOA1RECFYLNG9LCXCA3RGCFDBHT - F1MPP1LC3XC3GALnitiuqibUF
ALHA2RLOPLBYMD5PPNI7A4SMFNT - 3PMARCRAD1RIAL1MACVG
5FEGPARRCSCE3PALPIVA1APSHAHDS2PBFGF7GKNA6A4SM1BIRT
1PISAR1DTLE2PCLSRAW71IFIBBU1FRLK9BMSP11LCXCFWV
9FSSAR3PME551RIM1XSW
TCMR
Sellares
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TABLE  4 References	for	gene	lists
ABMR—Adama Multiplexed	color-	coded	probe-	based	gene	expression	assessment	for	clinical	molecular	diagnostics	in	formalin-	fixed	
paraffin-	embedded	human	renal	allograft	tissue.	Adam	B,	Afzali	B,	Dominy	KM,	Chapman	E,	Gill	R,	Hidalgo	LG,	
Roufosse	C,	Sis	B,	Mengel	M.	Clin	Transplant.	2016	Mar;30(3):295-	305.
ABMR—Halloran Molecular	diagnosis	of	antibody-	mediated	rejection	in	human	kidney	transplants.	Sellarés	J,	Reeve	J,	Loupy	A,	Mengel	
M,	Sis	B,	Skene	A,	de	Freitas	DG,	Kreepala	C,	Hidalgo	LG,	Famulski	KS,	Halloran	PF.	Am	J	Transplant.	2013	
Apr;13(4):971-	83.
ABMR—Venner The	molecular	landscape	of	antibody-	mediated	kidney	transplant	rejection:	evidence	for	NK	involvement	through	
CD16a	Fc	receptors.	Venner	JM,	Hidalgo	LG,	Famulski	KS,	Chang	J,	Halloran	PF.	Am	J	Transplant.	2015	
May;15(5):1336-	48.
ABMR—Roufosse Use	of	quantitative	real	time	polymerase	chain	reaction	to	assess	gene	transcripts	associated	with	antibody-	mediated	
rejection	of	kidney	transplants.	Dominy	KM,	Roufosse	C,	de	Kort	H,	Willicombe	M,	Brookes	P,	Behmoaras	JV,	Petretto	
EG,	Galliford	J,	Choi	P,	Taube	D,	Cook	HT,	Mclean	AG.	Transplantation.	2015	Sep;99(9):1981-	8.
DSAST—Halloran	(donor- 
specific	antibody– 
associated	transcripts)
NK	cell	transcripts	and	NK	cells	in	kidney	biopsies	from	patients	with	donor-	specific	antibodies:	evidence	for	NK	cell	
involvement	in	antibody-	mediated	rejection.	Hidalgo	LG,	Sis	B,	Sellares	J,	Campbell	PM,	Mengel	M,	Einecke	G,	Chang	J,	
Halloran	PF.	Am	J	Transplant.	2010	Aug;10(8):1812-	22.
C5-	Inh	Responds-
Lefaucheur/Loupy	
(complement	compo-
nent	5	inhibition	
treatment response–as-
sociated	transcripts)
Complement-	activating	anti-	HLA	antibodies	in	kidney	transplantation:	allograft	gene	expression	profiling	and	response	
to	treatment.	J	Am	Soc	Nephrol.	2017	Oct	17.	Lefaucheur	C,	Viglietti	D,	Hidalgo	LG,	Ratner	LE,	Bagnasco	SM,	Batal	I,	
Aubert	O,	Orandi	BJ,	Oppenheimer	F,	Bestard	O,	Rigotti	P,	Reisaeter	AV,	Kamar	N,	Lebranchu	Y,	Duong	Van	Huyen	JP,	
Bruneval	P,	Glotz	D,	Legendre	C,	Empana	JP,	Jouven	X,	Segev	DL,	Montgomery	RA,	Zeevi	A,	Halloran	PF,	Loupy	A.	J	
Am	Soc	Nephrol.	2017	Oct	17.
TCMR—Sellares Molecular	diagnosis	of	T	cell-	mediated	rejection	in	human	kidney	transplant	biopsies.	Reeve	J,	Sellarés	J,	Mengel	M,	Sis	
B,	Skene	A,	Hidalgo	L,	de	Freitas	DG,	Famulski	KS,	Halloran	PF.	Am	J	Transplant.	2013	Mar;13(3):645-	55.
TCMR—Halloran Real	Time	Central	Assessment	of	Kidney	Transplant	Indication	Biopsies	by	Microarrays:	The	INTERCOMEX	Study.	
Halloran	PF,	Reeve	J,	Akalin	E,	Aubert	O,	Bohmig	GA,	Brennan	D,	Bromberg	J,	Einecke	G,	Eskandary	F,	Gosset	C,	
Duong	Van	Huyen	JP,	Gupta	G,	Lefaucheur	C,	Malone	A,	Mannon	RB,	Seron	D,	Sellares	J,	Weir	M,	Loupy	A.	Am	J	
Transplant.	2017	Nov;17(11):2851-	2862.
TCMR—Venner Molecular	landscape	of	T	cell-	mediated	rejection	in	human	kidney	transplants:	prominence	of	CTLA4	and	PD	ligands.	
Venner	JM,	Famulski	KS,	Badr	D,	Hidalgo	LG,	Chang	J,	Halloran	PF.	Am	J	Transplant.	2014	Nov;14(11):2565-	76.
Common	rejection	
module	(CRM)—Sarwal
A	common	rejection	module	(CRM)	for	acute	rejection	across	multiple	organs	identifies	novel	therapeutics	for	organ	
transplantation.	Khatri	P,	Roedder	S,	Kimura	N,	De	Vusser	K,	Morgan	AA,	Gong	Y,	Fischbein	MP,	Robbins	RC,	Naesens	
M,	Butte	AJ,	Sarwal	MM.	J	Exp	Med.	2013	Oct	21;210(11):2205-	21.
Constant	of	rejection—
National	Institutes	of	
Health
The	immunologic	constant	of	rejection.	Wang	E,	Worschech	A,	Marincola	FM.	Trends	Immunol.	2008	Jun;29(6):256-	62.
Exhaustion—Wherry Molecular	and	cellular	insights	into	T	cell	exhaustion.	Wherry	EJ,	Kurachi	M.	Nat	Rev	Immunol.	2015	Aug;15(8):486-	99.
Tolerance	
(blood)—Rebolo-	Mesa
Biomarkers	of	tolerance	in	kidney	transplantation:	are	we	predicting	tolerance	or	response	to	immunosuppressive	
treatment?	Rebollo-	Mesa	I,	Nova-	Lamperti	E,	Mobillo	P,	Runglall	M,	Christakoudi	S,	Norris	S,	Smallcombe	N,	Kamra	Y,	
Hilton	R;	Indices	of	Tolerance	EU	Consortium,	Bhandari	S,	Baker	R,	Berglund	D,	Carr	S,	Game	D,	Griffin	S,	Kalra	PA,	
Lewis	R,	Mark	PB,	Marks	S,	Macphee	I,	McKane	W,	Mohaupt	MG,	Pararajasingam	R,	Kon	SP,	Serón	D,	Sinha	MD,	
Tucker	B,	Viklický	O,	Lechler	RI,	Lord	GM,	Hernandez-	Fuentes	MP.	Am	J	Transplant.	2016	Dec;16(12):3443-	3457.
GoCar—O’Connell	
(Genomics	of	Chronic	
Allograft	Rejection	
study)
Biopsy	transcriptome	expression	profiling	to	identify	kidney	transplants	at	risk	of	chronic	injury:	a	multicentre,	
prospective	study	O’Connell	PJ,	Zhang	W,	Menon	MC,	Yi	Z,	Schröppel	B,	Gallon	L,	Luan	Y,	Rosales	IA,	Ge	Y,	Losic	B,	Xi	
C,	Woytovich	C,	Keung	KL,	Wei	C,	Greene	I,	Overbey	J,	Bagiella	E,	Najafian	N,	Samaniego	M,	Djamali	A,	Alexander	SI,	
Nankivell	BJ,	Chapman	JR,	Smith	RN,	Colvin	R,	Murphy	B.	Lancet.	2016	Sep	3;388(10048):983-	93.
CADI	progression—
Menon	(chronic	allograft	
damage	index– 
associated	transcripts)
Intronic	locus	determines	SHROOM3	expression	and	potentiates	renal	allograft	fibrosis.	Menon	MC,	Chuang	PY,	Li	Z,	
Wei	C,	Zhang	W,	Luan	Y,	Yi	Z,	Xiong	H,	Woytovich	C,	Greene	I,	Overbey	J,	Rosales	I,	Bagiella	E,	Chen	R,	Ma	M,	Li	L,	
Ding	W,	Djamali	A,	Saminego	M,	O’Connell	PJ,	Gallon	L,	Colvin	R,	Schroppel	B,	He	JC,	Murphy	B.	J	Clin	Invest.	2015	
Jan;125(1):208-	21.
AKI—Einecke	(acute	
kidney	injury– 
associated	transcripts)
Molecular	phenotypes	of	acute	kidney	injury	in	kidney	transplants.	Famulski	KS,	de	Freitas	DG,	Kreepala	C,	Chang	J,	
Sellares	J,	Sis	B,	Einecke	G,	Mengel	M,	Reeve	J,	Halloran	PF.	J	Am	Soc	Nephrol.	2012	May;23(5):948-	58.
eGFR	later— 
Vitalone	(estimated	
glomerular	filtration	
rate–associated 
transcripts)
Transcriptional	profiling	of	belatacept	and	calcineurin	inhibitor	therapy	in	renal	allograft	recipients.	Vitalone	MJ,	Ganguly	
B,	Hsieh	S,	Latek	R,	Kulbokas	EJ,	Townsend	R,	Sarwal	MM.	Am	J	Transplant.	2014	Aug;14(8):1912-	21.
(Continues)
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3.3 | Alternatives to the DSA criterion in 
ABMR diagnosis
Compared	with	 the	previous	 (2007)	Banff	classification	 for	ABMR,	
in	which	peritubular	capillary	C4d	staining	was	required	in	addition	
to	microvascular	inflammation	(MVI;	glomerulitis	and/or	peritubular	
capillaritis)	and	DSAs	for	the	diagnosis	of	active	ABMR,21	the	Banff	
2013	classification,14	which	 introduced	C4d-	negative	ABMR,	has	a	
higher	sensitivity	for	ABMR	diagnosis	and	an	improved	association	
of	 ABMR	 diagnosis	 with	 graft	 outcome.22	 Furthermore,	 molecular	
studies	 of	 Gupta	 et	al23	 strongly	 validated	 the	 MVI	 sum	 score	 of	
(g	+	ptc)	≥2	required	for	diagnosis	of	ABMR	by	Banff	2013.	Still,	MVI,	
even	with	(g	+	ptc)	scores	of	≥2	and	as	high	as	5,	is	not	specific	for	
ABMR,23,24	 and	Sis	 et	al24	 found	 that	11%	of	patients	with	biopsy	
specimens	showing	 (g	+	ptc)	=	5	were	DSA	negative.	Nevertheless,	
MVI	 remains	 strongly	 associated	 with	 graft	 outcomes,25 and a 
Mast	cells—Mengel	(mast	
cell transcripts 
associated	with	IFTA)
Molecular	correlates	of	scarring	in	kidney	transplants:	the	emergence	of	mast	cell	transcripts.	Mengel	M,	Reeve	J,	
Bunnag	S,	Einecke	G,	Sis	B,	Mueller	T,	Kaplan	B,	Halloran	PF.	Am	J	Transplant.	2009	Jan;9(1):169-	78.
Plasma	cell—Einecke	
(plasma	cell–associated	
transcripts)
Expression	of	B	cell	and	immunoglobulin	transcripts	is	a	feature	of	inflammation	in	late	allografts.	Einecke	G,	Reeve	J,	
Mengel	M,	Sis	B,	Bunnag	S,	Mueller	TF,	Halloran	PF.	Am	J	Transplant.	2008	Jul;8(7):1434-	43.	
TOLs—Colvin	(tolerance-	
associated	transcripts)
RNA	expression	profiling	of	non-	human	primate	renal	allograft	rejection	identifies	tolerance.	Smith	RN,	Matsunami	M,	
Adam	BA,	Rosales	IA,	Oura	T,	Cosimi	AB,	Kawai	T,	Mengel	M,	Colvin	RB.	Am	J	Transplant	2017	In	press.
Virus	(virus-	specific	
transcripts:	BK,	
cytomegalovirus,	
Epstein–Barr	virus)
Unpublished
ABMR,	antibody-	mediated	rejection;	TCMR,	T	cell–mediated	rejection.
aAlso	contains	housekeeping	genes.
TABLE  4  (Continued)
F IGURE  1 Representative	cases	of	chronic	active	T	cell–mediated	rejection,	grades	1A	(A,	B)	and	1B	(C,	D).	Each	biopsy	specimen	shows	
widespread	interstitial	inflammation	(mainly	lymphocytes	in	A	and	B;	lymphocytes	with	plasma	cells	in	C	and	D)	with	accompanying	interstitial	
edema	in	areas	of	the	cortex	with	interstitial	fibrosis	and	tubular	atrophy	(i-	IFTA	score	3).	Both	biopsy	specimens	also	show	tubulitis	involving	
tubules	with	mild	to	moderate	atrophic	changes;	this	tubulitis	is	moderate	(t2)	in	A	and	B	and	severe	(t3)	in	C	and	D.	There	was	also	mild	tubulitis	
(t1)	in	nonatrophic	tubules	in	both	biopsy	specimens,	and	each	specimen	also	had	a	total	inflammation	(ti)	score	of	2,	although	this	cannot	be	
determined	from	the	photomicrographs.	While	both	biopsy	specimens	show	considerable	edema	associated	with	the	inflammation,	there	is	
also	interstitial	fibrosis	in	these	areas	as	is	most	evident	from	the	darker	staining	areas	of	the	interstitium	in	B	and	D.	The	yellow	arrows	indicate	
tubules	with	tubulitis;	the	tubules	so	indicated	are	the	same	tubules	in	the	low-	power	and	corresponding	high-	power	photomicrographs	(A,	B;	C,	
D).	Jones	methenamine	silver	stain;	original	magnification	100×	(A,	C)	or	400×	(B,	D;	scale	bars	in	A	and	C	indicate	50	µm)
A B
C D
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problem	with	clinical	application	of	the	Banff	2013/2015	criteria	re-
mains	what	should	be	done	in	cases	where	there	are	no	detectable	
DSAs	but	a	biopsy	specimen	otherwise	meeting	criteria	 for	ABMR	
(MVI	score	≥1	and	C4d-	positive;	MVI	score	≥2	and	C4d	negative).	
In	 such	 instances,	 testing	 for	 non-	HLA	 antibodies	 (eg,	 anti–angio-
tensin	 type	 1	 receptor)	 is	 strongly	 advised,	 although	 such	 testing	
is	not	done	at	all	centers	and	the	clinical	 implications	of	such	anti-
bodies	are	not	completely	understood.	While	the	limited	sensitivity	
of	C4d	in	the	diagnosis	of	ABMR	is	well	recognized	and	led	to	the	
incorporation	 of	 C4d-	negative	 ABMR	 into	 the	 Banff	 classification	
in	 2013,14	multiple	 studies	 have	 shown	 that	 C4d	 staining	 in	 peri-
tubular	 capillaries	 by	 immunofluorescence	 (IF)	 on	 frozen	 sections	
or	 immunoperoxidase	 on	 paraffin	 sections	 has	 a	 very	 high	 (>90%)	
specificity	 for	 the	 presence	of	DSAs	 if	 positive.26-28	 False-	positive	
C4d	staining	in	peritubular	capillaries	was	not	seen	in	studies	of	na-
tive	renal	biopsy	specimens	or	preimplantation	biopsy	specimens	of	
donor	kidneys.29,30	Accordingly,	it	was	agreed	that	C4d	staining	in	at	
least	10%	of	peritubular	capillaries	(C4d2	or	C4d3)	by	IF	on	frozen	
sections	 or	 in	 any	 peritubular	 capillaries	 by	 immunoperoxidase	 on	
paraffin	sections	(C4d	score	>0)	should	be	regarded	as	sufficient	for	
the	diagnosis	of	ABMR	in	the	presence	of	MVI	(ie,	meeting	criterion	
3	of	 the	classification),	 regardless	of	whether	detectable	DSAs	are	
present	(Table	5).
We	also	considered	possible	molecular	alternatives	to	the	DSA	
criterion.	Molecular	markers,	in	the	form	of	those	associated	with	
endothelial	 injury,	 were	 first	 introduced	 into	 criterion	 2	 of	 the	
F IGURE  2 Three	renal	allograft	biopsies	specimens	showing	inflammation	in	areas	of	interstitial	fibrosis	and	tubular	atrophy	(i-	IFTA)	with	
varying	densities	of	interstitial	fibrosis	and	degrees	of	interstitial	inflammation,	edema,	and	tubulitis,	using	3	different	histologic	stains.	The	
biopsy	specimen	in	A-	C	shows	dense	interstitial	fibrosis	but	also	widespread	and	focally	heavy	inflammation	in	the	sclerotic	interstitium	
(i-	IFTA	3)	with	tubulitis	involving	several	mildly	to	moderately	atrophic	tubules,	up	to	score	t3	(arrow,	B).	The	biopsy	specimen	in	D-	F	also	
shows	dense	interstitial	fibrosis,	but	milder	inflammation.	Although	the	inflammation	in	D-	F	is	fairly	diffuse,	this	was	not	true	in	other	areas	of	
cortex	with	fibrosis,	and	the	i-	IFTA	score	on	this	biopsy	was	2.	In	addition,	there	is	only	mild	tubulitis	(t1),	and	as	such,	this	biopsy	specimen	
did	not	meet	criteria	for	chronic	active	T	cell–mediated	rejection.	In	the	biopsy	specimen	in	G-I,	the	interstitial	fibrosis	is	focally	dense	and	
focally	less	so	with	interstitial	edema,	as	is	most	evident	on	the	trichrome	stain	in	I.	There	is	more	variable	inflammation	(overall	i-	IFTA	score	
was	2),	although	t2	tubulitis	is	evident	in	a	mildly	atrophic	tubule	(arrow,	G).	Hematoxylin	and	eosin	(H&E;	A,	D,	G),	periodic	acid–Schiff	
(PAS;	B,	E,	H),	and	Masson	trichrome	(C,	F,	I)	stains;	original	magnification	200×	(all	panels).	The	scale	bar	at	the	bottom	right	of	each	panel	
indicates	50	µm
A B C
D E F
G H I
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TABLE  5 Revised	Banff	2017	classification	of	antibody-	mediated	rejection	(ABMR)	and	T	cell–mediated	rejection	(TCMR)	in	renal	allografts:	
revisions	highlighted	in	boldface	type
Category 1: Normal biopsy or nonspecific changes
Category 2: Antibody-mediated changes
Active ABMR;	all	3	criteria	must	be	met	for	diagnosis
1.	Histologic	evidence	of	acute	tissue	injury,	including	1	or	more	of	the	following:
Microvascular	inflammation	(g	>	0	and/or	ptc	>	0),	in	the	absence	of	recurrent	or	de	novo	glomerulonephritis,	although	in	the	presence	of	acute	
TCMR,	borderline	infiltrate,	or	infection,	ptc	≥	1	alone	is	not	sufficient	and	g	must	be	≥	1
Intimal	or	transmural	arteritis	(v	>	0)1
Acute	thrombotic	microangiopathy,	in	the	absence	of	any	other	cause
Acute	tubular	injury,	in	the	absence	of	any	other	apparent	cause
2.	Evidence	of	current/recent	antibody	interaction	with	vascular	endothelium, including 1 or more of the following:
Linear	C4d	staining	in	peritubular	capillaries	(C4d2	or	C4d3	by	IF	on	frozen	sections,	or	C4d	>	0	by	IHC	on	paraffin	sections)
At	least	moderate	microvascular	inflammation	([g	+	ptc]	≥2)	in	the	absence	of	recurrent	or	de	novo	glomerulonephritis,	although	in	the	presence	
of	acute	TCMR,	borderline	infiltrate,	or	infection,	ptc	≥	2	alone	is	not	sufficient	and	g	must	be	≥1
Increased expression of gene transcripts/classifiers in the biopsy tissue strongly associated with ABMR, if thoroughly validated
3.	Serologic	evidence	of	donor-	specific	antibodies	(DSA	to	HLA	or	other	antigens).	C4d staining or expression of validated transcripts/classifiers as 
noted above in criterion 2 may substitute for DSA; however thorough DSA testing, including testing for non-HLA antibodies if HLA antibody 
testing is negative, is strongly advised whenever criteria 1 and 2 are met
Chronic	active	ABMR;	all	3	criteria	must	be	met	for	diagnosis2
1.	Morphologic	evidence	of	chronic	tissue	injury,	including	1	or	more	of	the	following:
Transplant	glomerulopathy	(cg	>0)	if	no	evidence	of	chronic	TMA	or	chronic	recurrent/de	novo	glomerulonephritis;	includes	changes	evident	by	
electron	microscopy	(EM)	alone	(cg1a)
Severe	peritubular	capillary	basement	membrane	multilayering	(requires	EM)3
Arterial	intimal	fibrosis	of	new	onset,	excluding	other	causes;	leukocytes	within	the	sclerotic	intima	favor	chronic	ABMR	if	there	is	no	prior	
history	of	TCMR,	but	are	not	required
2.	Identical	to	criterion	2	for	active	ABMR,	above
3.	Identical	to	criterion	3	for	active	ABMR,	above,	including	strong	recommendation	for	DSA	testing	whenever	criteria	1	and	2	are	met
C4d	Staining	without	Evidence	of	Rejection;	all	4	features	must	be	present	for	diagnosis4
1.	Linear	C4d	staining	in	peritubular	capillaries	(C4d2	or	C4d3	by	IF	on	frozen	sections,	or	C4d>0	by	IHC	on	paraffin	sections)
2. Criterion 1 for active or chronic, active ABMR not met
3. No molecular evidence for ABMR as in criterion 2 for active and chronic, active ABMR
4.	No	acute	or	chronic	active	TCMR,	or	borderline	changes
Category 3: Borderline changes
Suspicious	(Borderline)	for	acute	TCMR
Foci	of	tubulitis	(t	>	0)	with	minor	interstitial	inflammation	(i0	or	i1),	or	moderate-	severe	interstitial	inflammation	(i2	or	i3)	with	mild	(t1)	tubulitis;	
retaining	the	i1	threshold	for	borderline	with	t	>	0	is	permitted	although	this	must	be	made	transparent	in	reports	and	publications
No	intimal	or	transmural	arteritis	(v	=	0)
Category 4: TCMR
Acute	TCMR
Grade	IA Interstitial	inflammation	involving	>25%	of	nonsclerotic	cortical	
parenchyma	(i2	or	i3)	with	moderate	tubulitis	(t2)	involving	1	or	more	
tubules,	not	including	tubules	that	are	severely	atrophic5
Grade	IB Interstitial	inflammation	involving	>25%	of	nonsclerotic	cortical	
parenchyma	(i2	or	i3)	with	severe	tubulitis	(t3)	involving	1	or	more	
tubules,	not	including	tubules	that	are	severely	atrophic5
Grade	IIA1 Mild	to	moderate	intimal	arteritis	(v1),	with	or	without	interstitial	
inflammation	and/or	tubulitis
Grade	IIB1 Severe	intimal	arteritis	(v2),	with	or	without	interstitial	inflammation	
and/or	tubulitis
Grade	III1 Transmural	arteritis	and/or	arterial	fibrinoid	necrosis	of	medial	smooth	
muscle	with	accompanying	mononuclear	cell	intimal	arteritis	(v3),	with	
or	without	interstitial	inflammation	and/or	tubulitis
(Continues)
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ABMR	 classification	 in	 Banff	 2013.14	 Since	 that	 time,	 combina-
tions	 of	 transcripts	 have	 been	 introduced	with	 far	 greater	 spec-
ificity	 for	 ABMR,17-20	 although	 these	 molecular	 tests	 admittedly	
still	have	 limitations	and	are	not	yet	approved	as	diagnostic	tests	
by	 regulatory	bodies.	Hidalgo	et	al31	 introduced	a	 “DSA-	specific”	
transcript	 set	 (DSASTs)	 of	 mRNAs	 differentially	 expressed	 in	 bi-
opsy	 specimens	 from	 DSA-	positive	 and	 DSA-	negative	 patients,	
excluding	those	differentially	expressed	in	rejecting	versus	nonre-
jecting	biopsy	specimens,	although	these	studies	showed	DSASTs	
to	be	more	of	a	marker	for	ABMR	than	for	the	presence	of	DSAs.31 
A	more	 specific	molecular	marker	 for	ABMR	 is	 the	ABMR	classi-
fier,17-20	 consisting	 of	 30	 nonredundant	 probes,	 selected	 from	
comparisons	between	biopsy	specimens	with	versus	those	without	
histologic	changes	of	ABMR.	Data	from	Loupy	et	al19	showed	that	
adding	the	results	of	the	ABMR	classifier	to	histologic	findings	sig-
nificantly	improved	their	ability	to	diagnose	ABMR,	independently	
from	C4d	and	DSA.	Therefore,	despite	the	limitations	noted,	it	was	
thought	that	this	classifier	or	a	related	gene	set	could	potentially	
be	 used	 to	 satisfy	 criterion	 3	 in	 the	 diagnosis	 of	 ABMR,	 similar	
to	 C4d	 (Table	5).	 It	 should	 be	 stressed	 that	 for	 this	 to	 be	 done	
at	 any	 given	 center,	 the	 cut-	off	 value	 of	 such	molecular	 assess-
ment	 in	 the	diagnosis	of	ABMR	must	be	 independently	validated	
at	each	center	at	 this	point	 in	 time.	With	 technologies	becoming	
available	 to	 derive	 the	 molecular	 assessment	 (classifier	 or	 gene	
set)	from	formalin-	fixed	paraffin-	embedded	(FFPE)	routine	biopsy	
specimens,32,33	 multicenter	 validation	 should	 become	 feasible	 in	
the	near	future	through	collaborative	efforts	of	the	ongoing	Banff	
working	groups	(Table	1).
3.4 | Removal of the term “acute” from “acute/active 
ABMR”
In	Table	2	of	the	2013	Banff	Classification,14	it	is	noted	in	a	footnote	
that	lesions	classified	as	acute/active	ABMR	may	be	clinically	acute,	
smoldering,	or	 subclinical;	 this	qualifier	was	also	maintained	 in	 the	
2015 revision.1	Thus,	the	use	of	the	word	“acute”	in	the	term	“acute/
active	ABMR”	can	be	misleading,	and	it	was	elected	to	simply	refer	to	
lesions	of	ABMR	with	microvascular	injury	and	evidence	of	current	
or	 recent	 antibody	 interaction	with	graft	 endothelium	but	without	
morphologic	evidence	of	chronic	vascular	injury	(transplant	glomeru-
lopathy	[TG],	peritubular	capillary	basement	membrane	multilayering	
[PTCBML],	new-	onset	arterial	 intimal	fibrosis	[cv]),	simply	as	active 
ABMR,	 keeping	 the	 footnote	 from	 Banff	 2013	 (Table	5).	 A	major-
ity	 (62%)	 of	 meeting	 attendees	 responding	 to	 the	 survey	 agreed.	
However,	the	rationale	for	this	change	goes	beyond	simply	clarifying	
terminology	and	also	considers	the	likelihood	that	there	are	multiple	
clinicopathologic	forms	of	active	ABMR.	At	a	minimum,	these	include	
true	acute	ABMR,	typically	presenting	with	acute	graft	dysfunction	in	
highly	sensitized	graft	recipients	having	a	memory	humoral	response,	
presenting	early	posttransplantation	without	chronic	damage	to	the	
Chronic	Active	TCMR
Grade IA Interstitial inflammation involving >25% of the total cortex (ti score 2 or 
3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) 
with moderate tubulitis (t2) involving 1 or more tubules, not including 
severely atrophic tubules5; other known causes of i-IFTA should be 
ruled out
Grade IB Interstitial inflammation involving >25% of the total cortex (ti score 2 or 
3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) 
with severe tubulitis (t3) involving 1 or more tubules, not including 
severely atrophic tubules5; other known causes of i-IFTA should be 
ruled out
Grade II1 Chronic allograft arteriopathy (arterial intimal fibrosis with mononuclear 
cell inflammation in fibrosis and formation of neointima)
Updates	from	Banff	20151	are	indicated	in	boldface	type.
1It	should	be	noted	that	these	arterial	lesions	may	be	indicative	of	ABMR,	TCMR,	or	mixed	ABMR/TCMR.	“v”	lesions	and	chronic	allograft	arteriopathy	are	
only	scored	in	arteries	having	a	continuous	media	with	≥2	smooth	muscle	layers.
2Lesions	of	chronic	active	ABMR	can	range	from	primarily	active	lesions	with	early	transplant	glomerulopathy	(TG)	evident	only	by	EM	(cg1a)	to	those	
with	advanced	TG	and	other	chronic	changes	in	addition	to	active	microvascular	inflammation.	For	biopsy	specimens	showing	TG	and/or	peritubular	
capillary	basement	membrane	multilayering	in	the	absence	of	evidence	of	current/recent	antibody	interaction	with	the	endothelium	(criterion	2)	but	
with	 a	prior	 documented	diagnosis	 of	 active	or	 chronic	 active	ABMR	or	documented	prior	 evidence	of	DSA,	 the	 term	 “chronic	ABMR”	 should	be	
applied.
3Indicates	≥7	layers	in	1	cortical	peritubular	capillary	and	≥5	in	2	additional	capillaries,	avoiding	portions	cut	tangentially.
4The	clinical	significance	of	these	findings	may	be	quite	different	in	grafts	exposed	to	anti–blood	group	antibodies	(ABO-	incompatible	allografts),	where	
they	do	not	appear	to	be	injurious	to	the	graft	and	may	represent	accommodation.	However,	with	anti-	HLA	antibodies,	such	lesions	may	progress	to	
chronic	ABMR,	and	more	outcome	data	are	needed.
5A	severely	atrophic	tubule	is	defined	as	one	with	each	of	the	following	3	features:	a	diameter	<25%	of	that	of	unaffected	or	minimally	affected	tubules	
on	 the	biopsy,	 an	undifferentiated-	appearing,	 cuboidal	or	 flattened	epithelium,	and	pronounced	wrinkling	and/or	 thickening	of	 the	 tubular	basement	
membrane.
TABLE  5  (Continued)
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allograft;	smoldering	active	ABMR,	which	may	be	diagnosed	on	sur-
veillance	or	indication	biopsy	specimens	in	patients	who	most	often	
have	low-	level	DSAs	(de	novo	or	persistent/recurrent);	and	chronic	
active	 ABMR,	 which	 most	 often	 represents	 a	 continuum	 of	 the	
smoldering	form	should	the	 latter	not	be	diagnosed	and	treated	 in	
a	 timely	manner,	 frequently	 in	patients	with	 limited	compliance.	 In	
contrast	with	 true	acute	ABMR,	which	can	often	be	reversed	by	a	
combination	of	current,	standard-	of-	care	treatments	aimed	primarily	
at	removing	DSAs	(eg,	plasmapheresis,	rituximab,	intravenous	immu-
noglobulin),34,35	smoldering	active	ABMR	should	be	a	major	focus	for	
future	clinical	trials	of	novel	agents	designed	to	treat	active	ABMR	
and	prevent	de	novo	or	progressing	TG	by	mechanisms	other	than	
(or	in	addition	to)	DSA	removal.	In	summary,	the	word	“active”	in	the	
pathology	 report	 indicates	 ongoing	 disease	 activity	 highlighted	 by	
MVI	with	or	without	concomitant	chronic	remodeling	(TG,	PTCBML,	
IFTA,	cv)	of	the	allograft.
3.5 | Recommendations for use of molecular 
diagnostics
Molecular	diagnostics	were	first	introduced	into	the	Banff	classifi-
cation	in	2013,14	although	this	was	limited	to	ABMR	and	its	intro-
duction	was	as	much	 to	encourage	development	of	more	 specific	
and	more	universally	applicable	molecular	tests	as	to	be	used	in	di-
agnosing	ABMR	at	that	time.	That	former	goal	has	in	fact	come	to	
fruition,	and	multiple	groups	in	North	America	and	Europe	are	now	
applying	 molecular	 diagnostics	 in	 analyzing	 renal	 allograft	 biopsy	
specimens18-20—as	summarized	in	Tables	3	and	4.	Just	as	the	2013	
Banff	meeting	report14	put	forth	recommendations	regarding	taking	
a	sample	of	tissue	from	renal	allograft	biopsies	for	electron	micros-
copy	(EM)	and	guidelines	for	performing	EM	to	detect	early	changes	
of	transplant	glomerulopathy	(cg1a),	it	is	now	appropriate	to	recom-
mend	sampling	of	biopsy	tissue	for	molecular	studies	and	to	provide	
guidelines	for	when	such	studies	are	likely	to	be	helpful	diagnosti-
cally	(Table	6).	The	latter	specifically	include	situations	where	a	com-
bination	of	histologic,	immunohistologic,	and	serologic	data	remain	
equivocal	 for	diagnosis	of	ABMR,	such	as	when	the	biopsy	shows	
microvascular	 inflammation	(g	+	ptc	≥	2)	but	no	C4d	and	there	are	
no	detectable	DSAs;	in	biopsy	specimens	of	ABO-	incompatible	allo-
grafts	showing	(g	+	ptc	≥	2)	and	where	a	positive	C4d	is	not	helpful	
diagnostically36;	and	in	biopsy	specimens	of	ABO-	compatible	grafts	
where	there	 is	C4d	positivity	and	DSA	but	no	histologic	evidence	
of	rejection.	In	addition,	testing	for	transcript	sets	strongly	associ-
ated	with	 TCMR15,16,18,20	may	 also	 prove	 useful	 in	 differentiating	
borderline	infiltrates	 likely	to	 lead	to	development	of	overt	TCMR	
and/or	graft	fibrosis	from	those	that	are	not,	as	well	as	evaluating	
Histology/Banff scores/serology Differential diagnosis
Possible molecular 
test
Mild	MVI	(g		+		ptc	=	1) 
C4d	negative,	DSA	positive
ABMR	vs	no	ABMR ABMR	classifier17,40 
DSAST31,41
Moderate	to	severe	peritubular	
capillaritis	(ptc	≥2) 
No	glomerulitis	(g	=	0) 
TCMR	or	borderline 
C4d	negative,	DSA	positive
Pure	TCMR/borderline	vs	mixed	
ABMR	+	TCMR/borderline
ABMR	classifier17,40 
DSAST31,41
Moderate	to	severe	MVI	(g	+	ptc	
≥2) 
C4d	negative 
No	identifiable	anti-	HLA	DSA,	±	
non-	HLA	antibody
ABMR	vs	no	ABMR ABMR	classifier17,40 
DSAST31,41
No	MVI	(g	+	ptc	=	0) 
C4d	positive,	±	DSA 
ABO	compatible
ABMR	vs	no	ABMR ABMR	classifier17,40 
DSAST31,41
MVI	(g	+	ptc	>	0);	C4d	positive 
no	identifiable	anti-	HLA	DSA 
ABO	incompatible
ABMR	vs	no	ABMR ABMR	classifier17,40 
DSAST31,41
TG	(cg	>	0) 
No	or	mild	MVI	(g	+	ptc	≤	1) 
C4d	negative,	DSA	positive
Purely	chronic	ABMR	or	no	
ABMR	vs	chronic	active	ABMR
ABMR	classifier17,40 
DSAST31,41
Borderline	infiltrate TCMR	vs	no	TCMR TCMR	classifier42,43
Isolated	arteritis	(no	MVI	or	TCMR) 
C4d	negative,	±	DSA
TCMR	vs	ABMR	vs	mixed	
rejection vs no rejection
ABMR	classifier17,40 
DSAST31,41 
TCMR	Classifier42,43
ABMR,	 antibody-	mediated	 rejection;	ABO,	 blood	group	 antigens;	 cg,	Banff	 chronic	 glomerulopathy	
score;	DSA,	donor-	specific	antibody;	DSAST,	donor-	specific	antibody	specific	transcript;	g,	Banff	glo-
merulitis	score;	MVI,	microvascular	inflammation;	ptc,	Banff	peritubular	capillaritis	score;	TCMR,	T	cell–
mediated	rejection;	TG,	transplant	glomerulopathy.
TABLE  6 Recommended	indications	for	
use	of	molecular	diagnostics	in	renal	
allograft	biopsy	diagnosis
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the	 thresholds	 values	 for	 chronic	 active	 TCMR	 introduced	 in	 this	 
report	(Table	5).
It	should	be	noted	that	at	this	point	no	specific	Banff	recommen-
dations	are	given	regarding	which	molecular	classifiers/transcript	sets	
should	be	tested	for	or	the	platform(s)	used	to	assess	gene	expression.	
This	 includes	 the	decision	whether	 to	perform	molecular	studies	on	
freshly	sampled	tissue	or	FFPE,32,33	the	latter	having	the	advantage	of	
being	done	on	the	same	tissue	used	for	routine	histology	but	with	pos-
sible	 reduced	sensitivity	due	to	RNA	degradation	during	processing.	
In	all	cases,	molecular	analyses	need	to	be	validated	in	any	individual	
laboratory	 performing	 such	 testing,	 and	 gene	 expression	 thresholds	
significantly	associated	with	ABMR,	TCMR,	or	other	lesions	may	well	
be	 different	 in	 different	 laboratories	 using	 the	 same	 transcript	 sets	
and	platforms.	As	mentioned,	because	there	are	no	specific	lesions	for	
ABMR/TCMR,	no	specific	gene	would	be	per	se	relevant	for	discrim-
ination	 these	diseases.	A	holistic	molecular	approach	using	machine	
learning	and	classifiers	has	been	done	in	recent	years	and	has	provided	
valuable	 information	 for	 improving	 the	 classification	 and	prognostic	
assessment	of	rejection.19,37-39
As	 discussed,	 the	 changes	 made	 to	 the	 Banff	 classification	
in 201314	 stimulated	 many	 studies	 that	 largely	 validated	 those	
changes	but	also	led	to	additional	modification	of	the	classification	
presented	in	the	2015	meeting	report1	and	here.	Similarly,	it	is	an-
ticipated	that	the	changes	and	recommendations	made	in	this	meet-
ing	 report	will	 serve	 as	 a	 stimulus	 for	 studies	 testing	 the	 validity	
of	the	revised	diagnostic	criteria	for	TCMR	and	ABMR	with	respect	
to	predicting	patient	outcomes,	as	well	as	studies	directly	applying	
molecular	diagnostics	 in	 the	clinical	 setting	along	the	path	 toward	
molecular	consensus	described	in	the	2015	Banff	meeting	report.1 
The	ultimate	goals	are	not	only	to	improve	our	ability	to	predict	graft	
outcomes	but	also	to	better	guide	therapy,	including	in	those	cases	
where	histology	and	serology	alone	cannot	optimally	do	so,	leading	
to	improved	patient	outcomes	compared	with	the	current	standard	
of	care.
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